Condition: Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration · Sponsor: Avistone Biotechnology Co., Ltd.
This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS03 as monotherapy.
This description comes directly from the study's public registry record.
Avistone Clinical Study Information Center · 8610 84148921 · information.center@avistonebio.com
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Research Site | Fuzhou, Fujian, China | Recruiting |
| Research Site | Guangzhou, Guangdong, China | Recruiting |
| Research Site | Shanghai, Shanghai Municipality, China | Recruiting |
| Research Site | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06716138